Xenon Pharmaceuticals Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-06-03

Reporting Person: AULIN SHERRY (Chief Financial Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
No securities are beneficially owned.	0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.49	2026-03-10	Common Shares (32)		Direct
Stock Option (Right to Buy)	$8.40	2027-03-12	Common Shares (813)		Direct
Stock Option (Right to Buy)	$3.10	2027-10-22	Common Shares (2292)		Direct
Stock Option (Right to Buy)	$4.75	2028-03-11	Common Shares (6511)		Direct
Stock Option (Right to Buy)	$9.44	2029-09-15	Common Shares (18334)		Direct
Stock Option (Right to Buy)	$11.58	2030-03-11	Common Shares (22000)		Direct
Stock Option (Right to Buy)	$20.55	2031-03-11	Common Shares (22000)		Direct

Footnotes

F1: Not applicable.

F2: The shares subject to the option fully vested on December 31, 2019.

F3: The shares subject to the option fully vested on December 31, 2020.

F4: Vested 25% on October 23, 2018 and remaining 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

F5: Vested 25% on January 1, 2019 and remaining 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

F6: The shares subject to the option vest each monthly anniversary of the September 16, 2019 vesting commencement date over 3 years.

F7: Vested 25% on January 1, 2021 and remaining 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

F8: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.